⌘K

Login Start Free

Home/Filings/4/0001185185-24-000259

4//SEC Filing

Moran James P 4

Accession 0001185185-24-000259

CIK 0001326205other

View on SEC.gov Company Profile

Filed

Mar 14, 8:00 PM ET

Accepted

Mar 15, 9:05 PM ET

Size

24.9 KB

Accession

0001185185-24-000259

Insider Transaction Report

Form 4

Period: 2024-03-13

IGC Pharma, Inc.IGC

Director

Transactions

Exercise/Conversion
Restricted Stock Units
2024-03-13−33,333→ 33,333 total
→ Common Stock (33,333 underlying)
Award
Restricted Stock Units
2024-03-13+150,000→ 150,000 total
→ Common Stock (150,000 underlying)
Award
Restricted Stock Units
2024-03-13+100,000→ 100,000 total
Exp: 2034-03-31→ Common Stock (100,000 underlying)
Exercise/Conversion
Common Stock
2024-03-13+50,000→ 183,334 total
Exercise/Conversion
Common Stock
2024-03-13+33,334→ 216,667 total
Exercise/Conversion
Common Stock
2024-03-13+80,000→ 296,667 total
Exercise/Conversion
Common Stock
2024-03-13+28,500→ 325,167 total
Exercise/Conversion
Common Stock
2024-03-13+29,000→ 354,167 total
Exercise/Conversion
Restricted Stock Units
2024-03-13−50,000→ 0 total
→ Common Stock (50,000 underlying)
Exercise/Conversion
Restricted Stock Units
2024-03-13−80,000→ 160,000 total
→ Common Stock (80,000 underlying)
Exercise/Conversion
Restricted Stock Units
2024-03-13−57,500→ 142,500 total
Exp: 2033-03-31→ Common Stock (57,500 underlying)

Footnotes (7)

[F1]Represents 150,000 restricted shares of IGC common stock subject to vesting equally over three years starting on January 18, 2022, and then on March 2023 and 2024, as per the RSU Agreement with Director Moran.
[F2]On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting March 2023.
[F3]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting March 2024.
[F4]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved.
[F5]Each restricted stock unit represents a right to receive one share of IGC common stock.
[F6]On March 13, 2024, the Reporting Person was granted RSUs subject to vesting equally over three years starting March 2025.
[F7]On March 13, 2024, the Reporting Person was granted RSUs subject to vesting according to specific milestones set by the Company's Board of Directors. The RSUs vest when milestones are achieved.

Documents

1 file

4
ownership.xmlPrimary

Issuer

IGC Pharma, Inc.

CIK 0001326205

Entity typeother

Related Parties

1

filerCIK 0001907094

Filing Metadata

Form type: 4
Filed: Mar 14, 8:00 PM ET
Accepted: Mar 15, 9:05 PM ET
Size: 24.9 KB

View on SEC.gov